Results 131 to 140 of about 58,504 (176)

Single-cell RNA sequencing profiles drug activity within spatially engineered 3D cultures. [PDF]

Nat Commun
King JJ, Mowla A, Kretzmann JA, Bhalla N, Sugianto G, Norret M, Kadolsky UD, Iqbal M, Saxena A, Amos SE, Choi YS, Kennedy BF, Iyer KS, Smith NM, Evans CW.   +14 more
europepmc   +1 more source

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019-2024. [PDF]

Front Oncol
Fuldeore R, Tan CJ, Kimura T, Farrokhi P, Yang R, Willis C, Asche C, Stenehjem D.   +7 more
europepmc   +1 more source

A Comprehensive Review on Irinotecan-Induced Delayed Diarrhea: From Mechanisms to Therapeutic Options. [PDF]

Pharmaceuticals (Basel)
Wang Y, Li M, Hu Q, Liu J, Yang Q, Li Q, Zhu X, Dang H, Li H, Wang L, Peng B, Chen Y.   +11 more
europepmc   +1 more source

The phase I trial of preoperative short-course chemoradiotherapy with S-1/irinotecan and short-course radiation in locally advanced lower rectal cancer (SHOWTIME study). [PDF]

Radiat Oncol
Kojo K, Tanaka T, Yamanashi T, Miura H, Yokoi K, Kojima K, Yokota K, Kawakami S, Ishiyama H, Yamashita K, Kumamoto Y, Hiki N, Sato T, Naitoh T.   +13 more
europepmc   +1 more source

High therapeutic efficacy of triplet therapy in unresectable or metastatic colorectal cancer and its optimal application strategies. [PDF]

Int J Clin Oncol
Sakuyama H, Okuyama H, Tahara Y, Tsukamoto S, Kita I, Nomura K, Murakami A, Okita Y, Satake H, Kato T, Tsuji A.   +10 more
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source